Immune Response News and Research

RSS

Stanford University starts recruiting participants for swine flu vaccine clinical trial

The Stanford University School of Medicine is recruiting participants for a clinical trial to determine the safety of an experimental vaccine against the new H1N1 strain of influenza when the vaccine is combined with an immune-stimulating substance called an adjuvant. The trial will also examine whether use of the adjuvant improves the immune response to the vaccine.

31 Aug 2009

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass' proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential.

31 Aug 2009

TRAF6 protein can activate a cell signalling molecule associated with cancer

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

28 Aug 2009

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

IDRI (Infectious Disease Research Institute) announced today the start of a clinical trial in Sudan to test its leishmaniasis vaccine candidate for the treatment of post kala-azar dermal leishmaniasis (PKDL), a complication of visceral leishmaniasis (VL) which is observed in 50% of patients treated for VL in the country, predominantly affecting children.

28 Aug 2009

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

AVI BioPharma, Inc., a developer of RNA-based drugs, today announced that Hong Moulton, Ph.D., Director of Discovery Research, will give oral presentations highlighting improved analogues of AVI's phosphorodiamidate morpholino oligomer (PMO) chemistry at two upcoming scientific meetings.

28 Aug 2009

$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancer

Investigators at the Mayo Clinic Cancer Center have received a five-year, $11.5 million grant to translate research into treatments for women with ovarian cancer.

28 Aug 2009

Rutgers University Professor receives $3.5 million MERIT Award from NIH

Rutgers University Professor Dipak Sarkar has received a $3.5 million MERIT Award from the National Institutes of Health (NIH) to continue researching the damaging effects of alcohol on the nervous systems of the unborn.

27 Aug 2009

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Bio-Matrix Scientific Group, Inc. and Its majority owned subsidiary Entest BioMedical Inc. announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.

27 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, is accepting grant applications for a new initiative to establish a consortium of human immune profiling research centers.

25 Aug 2009

UCLA finds link between high cholesterol and osteoporosis

A new UCLA study sheds light on the link between high cholesterol and osteoporosis and identifies a new way that the body's immune cells play a role in bone loss

25 Aug 2009

CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US

CSL Biotherapies has announced the initiation of the company’s first U.S. clinical trials of its candidate Influenza A/H1N1 2009 vaccine. Study investigators will administer vaccinations to the first U.S. study volunteers today, August 24. The studies will determine the safety of CSL’s candidate vaccine and its ability to elicit an immune response (also referred to as immunogenicity) in adults and children.

24 Aug 2009

Wheat-free diet reduces the incidence of diabetes

Scientists at the Ottawa Hospital Research Institute and the University of Ottawa have discovered what may be an important clue to the cause of type 1 diabetes. Dr. Fraser Scott and his team tested 42 people with type 1 diabetes and found that nearly half had an abnormal immune response to wheat proteins. The study is published in the August 2009 issue of the journal Diabetes.

21 Aug 2009

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein-a cancer vaccine-that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

21 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Immunology researchers at UT Southwestern Medical Center have found that bacteria present in the human gut help initiate the body's defense mechanisms against Toxoplasma gondii, the parasite responsible for toxoplasmosis.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

H1N1 vaccine orders top 1 billion, WHO Says

"Northern hemisphere countries have so far ordered more than one billion doses of swine flu vaccine, the World Health Organisation said Tuesday, sparking warnings over shortages," Agence France-Presse reports. While some countries, including Greece, The Netherlands, Canada and Israel, have ordered enough vaccine to inoculate their citizens, "[o]thers, such as Germany, the United States, Britain and France, have put in orders that would cover between 30 and 78 percent of people," the news service writes.

19 Aug 2009

Immune Response News and Research

Stanford University starts recruiting participants for swine flu vaccine clinical trial

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

TRAF6 protein can activate a cell signalling molecule associated with cancer

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancer

Rutgers University Professor receives $3.5 million MERIT Award from NIH

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Combined therapy for acute leukemia shows promising results

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

UCLA finds link between high cholesterol and osteoporosis

CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US

Wheat-free diet reduces the incidence of diabetes

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

Advaxis awarded $210,000 for development of a dual antigen vaccine

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Steroid hormones found to affect gene activity

H1N1 vaccine orders top 1 billion, WHO Says

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News